Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Group 1 - A securities class action lawsuit has been filed against Replimune Group, Inc. alleging possible securities fraud or other unlawful business practices [5] - The lawsuit covers a class period from November 22, 2024, to July 21, 2025, with a lead plaintiff deadline of September 22, 2025 [5] - The trigger event for the lawsuit was the FDA's Complete Response Letter rejecting Replimune's Biologics License Application for RP1, citing inadequate clinical evidence from the IGNYTE trial [5] Group 2 - Following the FDA's announcement, Replimune's stock experienced a significant decline of 77.24%, closing at $2.81 per share after a drop of $9.52 [5]